Can Thymosin Alpha-1 Keep the Immune System Age-less? | Age-Less Top 20 Peptides

Age-Less Energy: The Real Science of SS-31 | Age-Less Top 20 Peptides

SS-31 — also known as elamipretide — occupies a category no other compound in this series can claim: it is the first mitochondria-targeted therapy ever to receive FDA approval. In this episode, Dr. Ethan traces the compound from its accidental discovery in a Weill Cornell pharmacology lab through to its September 2025 accelerated approval for Barth syndrome, unpacking the biology of cardiolipin — the inner mitochondrial membrane phospholipid whose decline with age sits at the centre of SS-31's entire mechanistic rationale — and explaining precisely why a peptide that concentrates over 1,000-fold inside the mitochondrial membrane represents a genuinely novel class of therapeutic tool. The mechanism is well-supported, the preclinical literature is large and independently replicated, and the clinical trial programme is the most rigorous of any compound covered in this series so far. The honest picture is more nuanced than the approval alone would suggest. The regulatory journey was long and difficult — an initial refusal to file, a subsequent rejection, and an eventual accelerated approval based on an intermediate endpoint in a rare paediatric disease population. The heart failure and AMD programmes remain in active development, not yet approved. And for the application most longevity-focused listeners are actually interested in — preserving mitochondrial function in a healthy ageing adult — there are no completed trials and no approved protocols. Dr. Ethan draws a precise line between what the approval actually means, what the active trial pipeline shows, and where the extrapolation to healthy ageing begins — and explains why SS-31 is simultaneously the most clinically credible mitochondrial compound in the longevity space and still some distance from a validated longevity intervention.

Age-Less Cognition: The Real Science of Pinealon | Age-Less Top 20 Peptides

Pinealon is one of the least discussed compounds in mainstream longevity medicine — and that obscurity is itself worth examining. Derived from pineal gland tissue and developed within a serious, decades-long Russian bioregulatory peptide research programme, it sits at the intersection of two of the most compelling areas in ageing biology: the decline of the pineal gland as a master regulator of circadian timing, and the emerging science of epigenetic modulation as a mechanism for restoring youthful gene expression patterns in ageing neurons. In this episode, Dr. Ethan Hausman-Marquis traces Pinealon from its origins in the St. Petersburg school of biogerontology through to its proposed mechanisms — BDNF-adjacent neuroprotection, circadian clock gene modulation, and a genuinely novel hypothesis about direct peptide-DNA interaction — and examines what the preclinical evidence actually shows. The honest answer is that Pinealon's evidence base is the thinnest in this series so far — geographically concentrated, not independently replicated, and nowhere near randomised controlled trial territory for any indication. But the biological target is one of the most legitimate in longevity medicine, and the mechanistic hypothesis, if it survives independent scrutiny, would represent something genuinely new in the neuroprotection space. This episode draws a precise line between what is established, what is plausible, and what remains speculation — and explains why the right response to Pinealon in 2026 is neither clinical enthusiasm nor dismissal, but a structured research agenda that has not yet been built.

Age-Less Cognition: The Real Science of SEMAX | Age-Less Top 20 Peptides

SEMAX is one of the most discussed cognitive compounds in the longevity and nootropic world — and arguably one of the most poorly understood. In this episode, Dr. Ethan does what this series always does: follows the science wherever it leads, without the hype and without the dismissiveness. The story of SEMAX starts not in a supplement company's marketing department, but in a Soviet government research institute in the 1980s, where neuropeptide scientists were asking a genuinely interesting question: could fragments of ACTH — the pituitary hormone best known for driving cortisol production — exert direct effects on the brain entirely independent of the adrenal axis? The answer was yes. And SEMAX was the engineered result: a stable, intranasally bioavailable heptapeptide designed to deliver those neuropeptide effects to the central nervous system. The mechanistic story is one of the more coherent in this series. SEMAX upregulates BDNF — brain-derived neurotrophic factor — in hippocampal and prefrontal circuits, the very regions most implicated in age-related cognitive decline. It modulates serotonin availability. It attenuates neuroinflammatory cascades. Each of those mechanisms has a plausible link to cognitive ageing, and together they form a rational basis for the compound's proposed effects. The evidence picture is more complicated. SEMAX has genuine peer-reviewed data — animal studies, Russian clinical trials in stroke and cerebrovascular disease, a 40-year research history. It is a licensed pharmaceutical in Russia, not a grey-market research chemical. But the clinical data has real structural limitations, and for the application most listeners are actually interested in — sharper cognition in a healthy ageing adult — the human randomised controlled trial evidence does not yet exist. Dr. Ethan also addresses the elephant in the room: the unusually consistent subjective reports from people who use SEMAX, what they actually tell us, and — critically — what they don't. And he covers the regulatory picture across the UK, EU, and US, the quality control risks of sourcing outside a licensed pharmaceutical supply chain, and what a properly designed research agenda for SEMAX would actually look like. If you've been offered SEMAX at a clinic, or you're considering it, or you simply want to understand why the gap between online enthusiasm and clinical evidence is so wide — this is the episode to start with.

Age-Less Repair: GHK-Cu The Swiss Army Knife of Peptides | Age-Less Top 20 Peptides

GHK-Cu — glycine-histidine-lysine complexed with copper — is one of the most structurally simple compounds in this series and one of the most mechanistically interesting. It is a tripeptide: three amino acids, naturally present in human plasma, saliva, and urine, with plasma concentrations that fall from roughly 200 nanograms per millilitre in young adults to near-undetectable levels by the time most people reach 60. That decline, and what it may mean for tissue maintenance and repair capacity across the lifespan, is the central biological question this episode addresses. The compound was first characterised in the early 1970s by Loren Pickart, who identified it in human plasma albumin fractions and noted its capacity to stimulate liver tissue regeneration in vitro. Subsequent decades of research — predominantly preclinical, predominantly in cell culture and animal models — have built a mechanistic picture of unusual breadth. GHK-Cu appears to modulate gene expression at scale: a 2010 analysis by Pickart and colleagues identified over 4,000 human genes regulated by GHK, with a roughly equal split between upregulation and downregulation. The upregulated genes cluster around wound healing, collagen synthesis, antioxidant defence, and nerve regeneration. The downregulated genes include inflammatory mediators, oncogenes associated with aggressive tumour behaviour, and genes involved in tissue degradation. In this episode, Dr. Ethan works through the mechanism in detail — the copper-dependent activation of superoxide dismutase, the upregulation of collagen and glycosaminoglycan synthesis, the suppression of TGF-beta 1-driven fibrosis, the activation of the Nrf2 antioxidant programme, and the VEGF-mediated angiogenic effects that underpin its wound-healing activity. He then addresses what the human evidence actually shows: robust data for topical wound healing applications, early but meaningful data for topical hair and skin applications, and a near-complete absence of completed randomised controlled trials for systemic or injectable use. The longevity application — using GHK-Cu to slow tissue ageing, support connective tissue integrity, and modulate the inflammatory environment systemically — is being actively explored in clinics across the UK, Europe, and the United States. That application is mechanistically coherent. It is not yet evidence-based in the clinical trial sense of that term. This episode explains the difference, and what it means for anyone navigating this space.

Tesamorelin: The Age-less Pulse of Growth Hormone | Age-Less Top 20 Peptides

In the mid-1990s, antiretroviral therapy was transforming HIV from a death sentence into a chronic condition — and creating an unexpected syndrome in its wake. Patients on the new combinations were developing visceral fat accumulation, peripheral fat loss, dyslipidaemia, and a measurably blunted growth hormone rhythm. A small Canadian biotech in Montréal saw the lever. Native GHRH had a half-life of seven minutes, cleaved almost instantly by an enzyme called DPP-IV. Their structural innovation — adding a single trans-3-hexenoic acid group to the N-terminus — blocked the cleavage site, extended the half-life to twenty-six minutes, and made an entire pharmacology clinically viable. That compound is Tesamorelin, and in 2010 it became one of the very few synthetic peptides ever to clear the full FDA approval pathway. In this episode, Dr. Ethan walks through the molecule properly. The forty-four amino acid sequence, the structural modification that makes it work, and the mechanism that distinguishes it from every other growth hormone strategy: Tesamorelin doesn't introduce GH, it activates the body's own pituitary to release GH in its natural pulsatile pattern, preserving somatostatin feedback and the physiological rhythm that exogenous rhGH abolishes. The episode follows the cascade from GHRH receptor binding through cAMP and PKA activation to pulsatile GH release, hepatic IGF-1 production, and the anabolic and lipolytic effects downstream. Then the human evidence — and this is where Tesamorelin sits in a category of its own. Two pivotal Phase III trials, fifteen years of post-marketing data, and a defined safety profile in HIV-associated lipodystrophy. Emerging Phase II data in MASLD showing meaningful reductions in hepatic fat. Exploratory work in cognitive function, sarcopenia, and healthy ageing — promising mechanistically, but not yet pivotal-trial grade. Dr. Ethan closes with an honest 2026 assessment: what the off-label use looks like, what the safety considerations actually are, what diagnostics any responsible Tesamorelin protocol requires, and where the gap remains between mechanistic plausibility and demonstrated efficacy outside the approved population. As ever — what we know, what we don't, and what the honest picture looks like for anyone navigating this field. The Science of Age-less Living. Hosted by Dr. Ethan Hausman-Marquis. Available on Spotify and Apple Podcasts.